nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acute promyelocytic leukemia
|
Tallman, Martin S. |
|
2014 |
27 |
1 |
p. 1- 1 p. |
artikel |
2 |
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
|
Grimwade, David |
|
2014 |
27 |
1 |
p. 53-61 9 p. |
artikel |
3 |
Conventional induction and post-remission therapy in APL: Have we arrived?
|
Sanz, Miguel A. |
|
2014 |
27 |
1 |
p. 33-38 6 p. |
artikel |
4 |
‘Corrigendum to “Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?” [Best Pract Res Clin Haematol (2013) 387–400]’
|
Itzykson, Raphael |
|
2014 |
27 |
1 |
p. 79- 1 p. |
artikel |
5 |
Editorial Board / Aims & Scope
|
|
|
2014 |
27 |
1 |
p. iii- 1 p. |
artikel |
6 |
Extramedullary disease in APL: A real phenomenon to contend with or not?
|
Ganzel, Chezi |
|
2014 |
27 |
1 |
p. 63-68 6 p. |
artikel |
7 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care
|
Iland, Harry J. |
|
2014 |
27 |
1 |
p. 39-52 14 p. |
artikel |
8 |
Index
|
|
|
2014 |
27 |
1 |
p. I- 1 p. |
artikel |
9 |
The coagulopathy in acute promyelocytic leukaemia – What have we learned in the past twenty years
|
Kwaan, Hau C. |
|
2014 |
27 |
1 |
p. 11-18 8 p. |
artikel |
10 |
Treatment of paediatric APL: How does the therapeutic approach differ from adults?
|
Kutny, Matthew A. |
|
2014 |
27 |
1 |
p. 69-78 10 p. |
artikel |
11 |
Triple A therapy: The molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide
|
Nichol, Jessica N. |
|
2014 |
27 |
1 |
p. 19-31 13 p. |
artikel |
12 |
Understanding the molecular pathogenesis of acute promyelocytic leukemia
|
Lo-Coco, Francesco |
|
2014 |
27 |
1 |
p. 3-9 7 p. |
artikel |